OTCM
SUSRF
Market cap296mUSD
Oct 11, Last price
11.84USD
Name
Surgical Science Sweden AB
Chart & performance
P/E
89.46
P/S
6.02
EPS
1.31
Vol. 1Y
—
Shs. 5Y
8.22%
Rev. 5Y
56.77%
Div Yld LY
—
Div Yld TTM
—
Revenues
992m
+12.25%
Net income
67m
-49.24%
CFO
80m
-41.85%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Surgical Science Sweden AB engages in the development of simulators for laparoscopic medical training. Its products include LapSim, for procedural simulation for cholecystectomy, appendectomy, advanced suturing and anastomosis, gynecology, hysterectomy, bariatrics, and nephrectomy; EndoSim, for endoscopy simulation; and TeamSim, for realistic training of collaboration within a surgery team. The company was founded by Anders Hyltander, David Löfstrand, and Anders Larsson on July 24, 1997 and is headquartered in Gothenburg, Sweden.
Key people
Tom Englund
Chief Executive Officer · since 2024
Anna Ahlberg
Chief Financial Officer · since 2018
Ran Bronstein
President - Research and Development · since 2021
Boaz Tal
Chief Operating Officer · since 2021
Niclas Olsson
Executive Vice President - Industry/OEM · since 2022
Anders Larsson
Chief Technology Officer · since 1999
Doron Zilberman
Executive Vice President of International Sales · since 2022
Inbal Mazor
Executive Vice President Products and Marketing · since 2022
Jan Bengtsson
Director · since 2011
Roland Bengtsson
Director · since 2025
Gisli Hennermark
Director · since 2024
Independent Director · since 2017
Henrik Falconer
Independent Director · since 2021
Tommy Forsell
Independent Director · since 2022
Independent Director · since 2021
Headquarters & legal address
Drakegatan 7A, 3 vån
Göteborg, O 412 50
SE
Göteborg, O 412 50
SE
Address
Drakegatan 7A, 3 van
Goteborg, O 412 50
SE
Goteborg, O 412 50
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||